5-HT1B receptor activation produces rapid antidepressant-like effects in rodents.

Ketamine is noted for its rapid onset antidepressant response and effectiveness in patients with treatment resistant depression. While most research has focused on glutamatergic mechanisms, recent studies show that antidepressant-like effects in rodents are dependent upon the serotonergic (5-HT) system and suggest a potential contribution of the 5-HT1B receptor. In this study we utilized CP-94253 to examine whether 5-HT1B receptor agonism produces rapid and sustained antidepressant-like effects, focusing on rodent models and treatment approaches commonly used to demonstrate the differentiated response to ketamine. We first confirmed that CP-94253 is a potent 5-HT1B agonist in vitro and that CP-94253 occupies brain 5-HT1B receptors at the doses tested. CP-94253 reduced immobility in the mouse forced swim test (FST) and exhibited a prominent antidepressant signature in the mouse-behavior phenotyping platform SmartCube®. When examined 24 h after acute treatment, CP-94253 reduced FST immobility in both naïve rats and in rats receiving chronic interferon alpha treatment. Ex vivo hippocampal long-term potentiation was also enhanced in naïve rats receiving acute CP-94253 treatment, 24 h prior to the recordings. In mice exposed to chronic social defeat stress, antidepressant-like effects in the tail suspension and sucrose preference tests were seen 1 h and 24 h after acute treatment, respectively. Finally, whole brain c-fos imaging in mice showed that CP-94253 modulates neuronal activity in discrete brain regions including the lateral habenula circuit implicated in depression and the ketamine treatment response. Collectively these results support the further investigation of 5-HT1B agonism as a novel treatment approach for major depressive disorder.

• Publication year

  2024

• Venue

  Pharmacology, Biochemistry and Behavior

• Publication date

  2024-11-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.pbb.2024.173917PMID 39608648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine

  2023cited by this paper
• Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

  2023cited by this paper
• Ketamine: Mechanisms and Relevance to Treatment of Depression.

  2023cited by this paper
• Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials

  2023cited by this paper
• Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments

  2023cited by this paper
• Bridging rapid and sustained antidepressant effects of ketamine.

  2023cited by this paper
• Effects of the serotonin 5-HT1B receptor agonist CP 94253 on the locomotor activity and body temperature of preweanling and adult male and female rats.

  2022cited by this paper
• 5-HT1B receptor-AC-PKA signal pathway in the lateral habenula is involved in the regulation of depressive-like behaviors in 6-hydroxydopamine-induced Parkinson’s rats

  2022cited by this paper
• Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin

  2022cited by this paper
• Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review

  2022cited by this paper
• Serotonin 5-HT1B receptors mediate the antidepressant- and anxiolytic-like effects of ventromedial prefrontal cortex deep brain stimulation in a mouse model of social defeat

  2022cited by this paper
• Sex-specific effects of social isolation stress and ketamine on hippocampal plasticity.

  2021cited by this paper
• Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD

  2021cited by this paper
• A Meta-Analysis of 5-Hydroxytryptamine Receptor 1B Polymorphisms With Risk of Major Depressive Disorder and Suicidal Behavior

  2021cited by this paper
• A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes.

  2021cited by this paper
• A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression

  2020cited by this paper
• An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence Microscopy

  2020cited by this paper
• Circuits and functions of the lateral habenula in health and in disease

  2020cited by this paper
• Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

  2020cited by this paper
• Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression

  2020cited by this paper
• 5-HT1B Receptor-Mediated Activation of ERK1/2 Requires Both Gαi/o and β-Arrestin Proteins.

  2019cited by this paper
• Reducing the global burden of depression: a Lancet-World Psychiatric Association Commission.

  2019cited by this paper
• Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine.

  2019cited by this paper
• Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain

  2019cited by this paper
• SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action

  2019cited by this paper
• Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.

  2019cited by this paper
• Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.

  2019cited by this paper
• Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

  2019cited by this paper
• Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine.

  2019cited by this paper
• Ketamine blocks bursting in the lateral habenula to rapidly relieve depression

  2018cited by this paper
• Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain

  2018cited by this paper
• Lateral habenula in the pathophysiology of depression.

  2018cited by this paper
• The 5-HT1B receptor - a potential target for antidepressant treatment

  2018cited by this paper
• S-Ketamine Mediates Its Acute and Sustained Antidepressant-Like Activity through a 5-HT1B Receptor Dependent Mechanism in a Genetic Rat Model of Depression

  2018cited by this paper
• Effect of Ketamine on LTP and NMDAR EPSC in Hippocampus of the Chronic Social Defeat Stress Mice Model of Depression

  2018cited by this paper
• Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)

  2018cited by this paper
• Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?

  2018cited by this paper
• The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex

  2017cited by this paper
• Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant‐like activity in BALB/cJ mice

  2017cited by this paper
• The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review

  2017cited by this paper
• Preclinical Evidence That 5-HT1B Receptor Agonists Show Promise as Medications for Psychostimulant Use Disorders

  2017cited by this paper
• Effects of a 5-HT1B Receptor Agonist on Locomotion and Reinstatement of Cocaine-Conditioned Place Preference after Abstinence from Repeated Injections in Mice

  2017cited by this paper
• Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine

  2017cited by this paper
• Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder.

  2016cited by this paper
• KETAMINE FOR TREATMENT‐RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE

  2016cited by this paper
• Precision psychiatry: a neural circuit taxonomy for depression and anxiety.

  2016cited by this paper
• A Lack of Serotonin 1B Autoreceptors Results in Decreased Anxiety and Depression-Related Behaviors

  2016cited by this paper
• Mapping of Brain Activity by Automated Volume Analysis of Immediate Early Genes.

  2016cited by this paper
• The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

  2016cited by this paper
• Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine

  2016cited by this paper
• Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression

  2016cited by this paper
• Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression

  2016cited by this paper
• Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus.

  2015cited by this paper
• Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression

  2015cited by this paper
• R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

  2015cited by this paper
• Resolving the neural circuits of anxiety

  2015cited by this paper
• Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats.

  2015cited by this paper
• Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

  2015cited by this paper
• Highthroughtput analysis of behavior for drug discovery

  2015cited by this paper
• 5HT(1B) receptor-mediated pre-synaptic depression of excitatory inputs to the rat lateral habenula.

  2014cited by this paper
• Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model.

  2014cited by this paper
• Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex.

  2014cited by this paper
• Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.

  2014cited by this paper
• iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging.

  2014cited by this paper
• Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

  2013cited by this paper
• GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

  2013cited by this paper
• Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism

  2013cited by this paper
• Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression

  2013cited by this paper
• A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers

  2013cited by this paper
• Synaptic Dysfunction in Depression: Potential Therapeutic Targets

  2012cited by this paper
• Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder

  2011cited by this paper
• Rapid, Computer Vision-Enabled Murine Screening System Identifies Neuropharmacological Potential of Two New Mechanisms

  2011cited by this paper
• Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission

  2011cited by this paper
• Glycogen Synthase Kinase-3β Is a Functional Modulator of Serotonin-1B Receptors

  2011cited by this paper
• Behavioral animal models of depression

  2010cited by this paper
• A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats.

  2009cited by this paper
• What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.

  2009cited by this paper
• SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A

  2009cited by this paper
• Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects.

  2008cited by this paper
• Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system.

  2008cited by this paper
• The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats.

  2007cited by this paper
• Rodent Models of Depression: Forced Swim and Tail Suspension Behavioral Despair Tests in Rats and Mice

  2007cited by this paper
• Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine.

  2006cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

  2006cited by this paper
• A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

  2006cited by this paper
• Risk of ischemic complications related to the intensity of triptan and ergotamine use

  2006cited by this paper
• Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: a possible mechanism of action.

  2005cited by this paper
• Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression

  2004cited by this paper
• Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test.

  2004cited by this paper
• Serotonin1B receptors: from protein to physiological function and behavior.

  2004cited by this paper
• mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes.

  2004cited by this paper
• Triptans in migraine

  2004cited by this paper
• Comorbidity of migraine and depression

  2003cited by this paper
• Pharmacological characterization of 5‐HT1B receptor‐mediated inhibition of local excitatory synaptic transmission in the CA1 region of rat hippocampus

  2003cited by this paper
• Effects of combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats.

  2002cited by this paper
• Stimulation of serotonin1B receptors induces conditioned place aversion and facilitates cocaine place conditioning in rats

  2002cited by this paper
• 5-HT(1B) mrna regulation in two animal models of altered stress reactivity.

  2002cited by this paper
• The role of 5‐HT1B receptors in the regulation of serotonin cell firing and release in the rat brain

  2001cited by this paper
• Activation of Akt1 by human 5-hydroxytryptamine (serotonin)1B receptors is sensitive to inhibitors of MEK.

  2001cited by this paper

• An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice.

  2026cites this paper
• Appraisal of the validity of preclinical investigations to predict the efficacy of psychedelic drugs as fast-acting antidepressants.

  2025cites this paper
• Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics.

  2025cites this paper